Home › Burkitt Lymphoma › North Carolina › Durham

Pag-aaral pangklinika para sa Burkitt Lymphoma sa Durham, NC

Isang pag-aaral para sa Burkitt Lymphoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Durham. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

Nagre-recruitPhase 2

Duke University Medical Center, Durham
UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo

366 Days – 46 Years · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Nagre-recruitPhase 3

UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo

Edad 18 hanggang 39 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT03150693

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Nagre-recruitPhase 2

Duke University Medical Center, Durham
UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo

365 Days · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

Nagre-recruitPhase 3

Duke University, Durham

Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT07648264

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Nagre-recruitPhase 2

Duke University Medical Center, Durham
UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo

Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Set 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Nagre-recruitPhase 3

Duke University Medical Center, Durham
UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo

365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

Nagre-recruitPhase 1/2

University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi ang layo

Edad 13 hanggang 90 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06533579

Registry of Older Patients With Cancer

Nagre-recruitObservasyonal na pag-aaral

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi ang layo

Edad 65 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT01137825

Study of SGR-1505 in Mature B-Cell Neoplasms

Nagre-recruitPhase 1

Duke University, Durham

Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT05544019

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Nagre-recruitObservasyonal na pag-aaral

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi ang layo

Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 27, 2025 · NCT01137643

Pag-aaral para sa Burkitt Lymphoma sa ibang lungsod

Iba pang pag-aaral sa Durham

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.